✦ LIBER ✦

Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

✍ Scribed by Jean–Frédéric Colombel; William J. Sandborn; Paul Rutgeerts; Robert Enns; Stephen B. Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D. Kent; Paul F. Pollack

Book ID: 119759599
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 712 KB
Volume: 132
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2006.11.041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adalimumab Induces and Maintains Clinica

Adalimumab Induces and Maintains Clinical Response and Remission in Patients With Active Crohn’s Disease: Results of the CHARM Trial

✍ J. Colombel; W.J. Sandborn; P. Rutgeerts; R. Enns; S.B. Hanauer; P. Remo; S. Sch 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Adalimumab for the induction and mainten

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

✍ Mamoru Watanabe; Toshifumi Hibi; Kathleen G. Lomax; Susan K. Paulson; Jingdong C 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 813 KB

Effect of adalimumab on clinical laborat

Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial

✍ David T. Rubin; Parvez Mulani; Jingdong Chao; Paul F. Pollack; Arielle G. Bensim 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 788 KB

Adalimumab safety in global clinical tri

Adalimumab safety in global clinical trials of patients with Crohn's disease

✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr

P243 Subgroup analysis of the placebo-co

P243 Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease

✍ S. Schreiber; W. Reinisch; J.-F. Colombel; W. Sandborn; A. Robinson; B. Huang; K 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 49 KB

Subgroup analysis of the placebo-control

Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

✍ Schreiber, S.; Reinisch, W.; Colombel, J.F.; Sandborn, W.J.; Hommes, D.W.; Robin 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 419 KB